Heart Failure Research
Heart failure, also known as congestive heart failure or CHF, is an inability of the heart to pump sufficient blood around the body.Heart failure typically occurs secondary to an existing pathology that alters cardiac function. Examples of syndromes that can precede heart failure include myocardial infarction, arrhythmia or infection. These can also cause dilated cardiomyopathy, a condition which accounts for approximately one third of all cases of heart failure. The pathogenesis of heart failure is cyclical and progressive; endogenous mechanisms, which are activated during heart failure in an attempt to counteract the symptoms, actually worsen cardiac function. Cardiac dysfunction, either systolic or diastolic, triggers a decrease in stroke volume and a resultant increase in cardiac output. In healthy individuals the body responds to decreases in cardiac output by initiating the renin-angiotensin-aldosterone system (RAAS) to promote fluid retention, and also by activating the sympathetic nervous system to cause peripheral vasoconstriction. Under normal circumstances this counteracts the imbalance in stroke volume, restoring cardiac output to normal levels. In patients with heart failure the increase in blood volume, together with the heightened peripheral resistance and elevated levels of circulating catecholamines, causes an increased load on the already weakened ventricles with each contraction, and the stroke volume does not return to normal levels. Repeated cycles of this process further weaken the ventricle walls, prompting ventricular hypertrophy and a decreased force of contraction.
Heart Failure Research Products Targets
- PI 3-kinase (22)
- Others (7)
- Mineralocorticoid Receptor (7)
- Angiotensin-Converting Enzyme (8)
- NO donors and precursors (9)
- nNOS (5)
- iNOS (11)
- eNOS (1)
- Angiotensin AT2 Receptor (3)
- Angiotensin AT1 Receptor (9)
- NKCC (2)
- Adrenergic α2 Receptor (33)
- Adrenergic α1 Receptor (22)
- Adrenergic β2 Receptor (6)
- Adrenergic β1 Receptor (7)
Products for Heart Failure Research - Page 15
- Cat.No. Product Name Information/Activity
-
BCC6950
Spermine NONOate
Slow NO releasing agent
-
BCC6746
L-Canavanine sulfate
L-Canavanine sulfate is a selective inhibitor of inducible NO synthase.
-
BCC2865
L-NAME hydrochloride
L-NAME hydrochloride inhibits NOS with an IC50 of 70 μM. L-NAME is a precursor to NOS inhibitor L-NOARG which has an IC50 value of 1.4 μM.
-
BCC5674
7-NINA
161467-34-1
-
BCC6713
7-Nitroindazole
2942-42-9
-
BCC6788
L-NMMA acetate
L-NMMA acetate is a nitric oxide synthase inhibitor of all NOS isoforms including NOS1, NOS2, and NOS3. The Ki values for nNOS (rat), eNOS (human), and iNOS (mouse) are approximately 0.18, 0.4, and 6 µM, respectively.
-
BCC2864
H-Arg(NO2)-OH
2149-70-4
-
BCC6847
TRIM
25371-96-4


